Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors
摘要:
Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors. By optimizing both the N-8 substituent and the biaryl region of the inhibitors we obtained single digit nanomolar compounds such as 37 with excellent selectivity for Plk-2 over Plk-1. When dosed orally in rats, compound 37 demonstrated a 41-45% reduction of pS129-alpha-synuclein levels in the cerebral cortex. (C) 2013 Elsevier Ltd. All rights reserved.
[EN] PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE<br/>[FR] PTÉRIDINONES EN TANT QU'INHIBITEURS DE POLO-LIKE KINASE
申请人:ELAN PHARM INC
公开号:WO2011079114A1
公开(公告)日:2011-06-30
The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
mammalian cells, and as a consequence is an attractive target for selective inhibition. This paper describes the discovery of a novel family of HCV NS5B non-nucleoside inhibitors inspired by the bioisosterism between sulfonamide and phosphonamide. Systematic structural optimization in this new series led to the identification of IDX375, a potent non-nucleoside inhibitor that is selective for genotypes
Alkylation and condensation reactions of N,N-dibenzylglycine esters: synthesis of α-amino acid derivatives
作者:Brian D. Gray、Peter W. Jeffs
DOI:10.1039/c39870001329
日期:——
Upon deprotonation N,N-dibenzylglycineesters undergo alkylation and condensationreactions at the α-carbon atom with various electrophiles.
N脱质子后,N-二苄基甘氨酸酯会在α-碳原子上与各种亲电试剂发生烷基化和缩合反应。
Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors
作者:James S. Scott、David J. Berry、Hayley S. Brown、Linda Buckett、David S. Clarke、Kristin Goldberg、Julian A. Hudson、Andrew G. Leach、Philip A. MacFaul、Piotr Raubo、Graeme Robb
DOI:10.1039/c3md00156c
日期:——
Monoacylglycerolacetyltransferase-2 (MGAT2) is a potential target for the treatment of type II diabetes. We report here the optimisation of a series of MGAT2 inhibitors with regard to their potency and permeability. Improvements in permeability, as measured by increased flux in a Caco-2 assay, were achieved through substitution at the 9-position of the core. We propose that reduction of the NH hydrogen-bond donor strength was primarily responsible for these effects.